«C¤Ö¦~±wª`·N¤O¤£¨¬¹L°Ê¯g 5%¥¼½T¶EÀò¶}ºë¯«¯f³B¤èÃÄ
(¦hÛ¦h18¤é¥[·sªÀ¹q)¬ã¨s¤Hûµo²{¡M¦w¬Ù¨àµ£¤Î«C¤Ö¦~±wª`·N¤O¤£¨¬¹L°Ê¯g(attention deficit hyperactivity disorder)¡M¨C20¤H¦³1¤HÀò¶}ºë¯«¯f³B¤èÃĪ«¡M¦Ó¥L̨S¦³½T¶Eºë¯«¯f¡C
Á{þHµû¦ô¬ì¾Ç¬ã¨s©Ò(Institute for Clinical Evaluative Sciences)ªº¬ã¨sµo²{¡MÂå¥Í¬°12%ª`·N¤O¤£¨¬¹L°Ê¯gªº¨àµ£¡N«C¤Ö¦~±wªÌ¶}ºë¯«¯fÃĪ«¡M¨Ò¦pºû«ä³q(Risperdal)¡B¶ø´á¥(Zyprexa)¡N«ä·ç±d(Seroquel)¡C
¬ã¨s©Òºë¯««O°·»PÃÄÅ}¶µ¥Øt³d¤H¡B¬ã¨s³ø§i¸ê²`¼¶¼g¤H¬ì}¨È§JÂå¥Í(Dr. Paul Kurdyak)»¡¡R¡u§ÚÌÀ˵ø¸ê®Æ¡M¬d¬Ýª`·N¤O¤£¨¬¹L°Ê¯g¨àµ£»P«C¤Ö¦~ªº±¡ªp¡Mµo²{¥u¦³«Ü¤Ö¼Æ¤H¦³¸Ó¥Îºë¯«¯fÃĪ«ªºª¬ªp¡M¦n¹³Ä¼Æ{¯g¡Bºë¯«¤Àµõ¯g¡C¡v
¬ì}¨È§J¸ÑÄÀ¡Mª`·N¤O¤£¨¬¹L°Ê¯gÅU¦W«ä¸q¡M¯gª¬¥]¬A¡RÃø¥H¶°¤¤ª`·N¤O¡Bļ°Ê¤£¦w¡M¹ï«Äµ£ªº¾Ç·~¦³«Ü¤j¼vÅT¡C
¤Wz¬ã¨s³ø§i©P¤T¦b¡m¥[®³¤jºë¯«¯f¾Ç´Á¥Z¡n(Canadian Journal of Psychiatry)µoªí¡M¬ã¨s¤Hû¥ÎÀH¾÷©â¼Ë¤è¦¡¡MÀË°Q¦w¬Ù10,000¦W1¨ì24·³©~¥ÁªºÂåÀø¬ö¿ý¡M¬d¬Ýª`·N¤O¤£¨¬¹L°Ê¯g¤Î¨ä¥L¶E¯gªº«O°·¬ö¿ý¡N³B¤èÃĪ«¡B«O°·ªA°Èµ¥¼Æ¾Ú¡C
¬ã¨s¤Hûµo²{¡M5%©Î536¦Wªº¨àµ£»P«C¤Ö¦~½T¶Eª`·N¤O¤£¨¬¹L°Ê¯g¡C¦b¨â©Ê¤§¶¡¡M¨k©Ê¶E¶E¦¹¯gªº¤ñ¨Ò¡M¤ñ¤k©Ê°ª2¡N3¿¡C
«C¦~¤H½T¶Eª`·N¤O¤£¨¬¹L°Ê¯g¡M¤j¬ù70%ªA¥Î§Q¥L¯à(Ritalin)¡Bªü±o©Ô(Adderall)ÃĪ«¡M¨º¬O³oÃþ¯gª¬ªº¼Ð·Ç¡B²Ä¤@½uÃĪ«ªvÀø¤è¦¡¡MÂå¥Í¤S¬°¤j¬ù20%ªº¯fµ£¶}§Ü§íÆ{¯gÃĪ«¡C¬ì}¨È§J«ü¥X¡MÂå¥Íµ¹ª`·N¤O¤£¨¬¹L°Ê¯g¯f¤H¶}§Ü§íÆ{ÃĪ«¡M¤@ÂI¤]¤£©_©Ç¡M¦]¬°³oÃþ¯f¤H³q±`¦³§íÆ{©MµJ¼{¯gª¬¡C
¥L»¡¡R¡u¥O¤H·N¥~ªºË¬O¡M12%ªºª`·N¤O¤£¨¬¹L°Ê¯g¯fµ£Àò±o§Üºë¯«¯fÃĪ«¡C¡v¥L¸ÑÄÀ»¡¡M³oºØÃĪ«¦³ÂíÀR§@¥Î¡C
¥t¤@¤è±¡M§Üºë¯«¯fÃĪ«¦³°Æ§@¥Î¡M¯f¤HªºÅé«ÅãµÛ¼W¥[¡M¨Ã¦³¾ÉP¿}§¿¯fªº·ÀI¡C